



Product Information

Product ID I5210

CAS No. 941678-49-5

Chemical Name

Synonym Ruxolitinib

Formula C₁₇H₁₈N₆

Formula Wt. 306.37

Melting Point


Purity ≥98%

Solubility DMSO 61 mg/mL (199.1 mM)
Ethanol 61 mg/mL (199.1 mM)
Water Insoluble

Store Temp -20°C

Ship Temp Ambient

Description INCB018424 is an inhibitor of JAK1/2 that is clinically used to treat rheumatoid arthritis and myelofibrosis. INCB018424 exhibits anticancer, anti-inflammatory, and antiviral activities. In myeloma cells, INCB018424 inhibits cell growth. INCB018424 also inhibits in vitro infection by HIV-1, HIV-2, and SHIV by preventing viral replication in lymphocytes. In animal models of CCL4-induced hepatic injury, INCB018424 prevents inflammation by decreasing neutrophil and macrophage infiltration, suppressing activation of NF-κB, and limiting release of TNF-α, IL-10, and IL-1β.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
I5210	5 mg	\$97.90
I5210	25 mg	\$320.90
I5210	50 mg	\$498.10

References Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. *Blood*. 2014 Dec 18;124(26):3924-31. PMID: 25352124.

Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. *Chem Biol Interact*. 2014 Sep 5;220:116-27. PMID: 24973641.

Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. *Antimicrob Agents Chemother*. 2014;58(4):1977-86. PMID: 24419350.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.